Torii Pharmaceutical Co., Ltd.
TRXPF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -57,969,963.80 | -4,306,895.35 | 2,109,334.18 | -12,410,702.77 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 16,161,529,983.54 | 110,389,460.02 | 93,365,788.68 | 106,677,328.84 |
| Quality | ||||
| ROIC | 0.01% | 1.05% | 1.29% | 0.97% |
| Gross Margin | 42.77% | 45.11% | 29.35% | 45.21% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -3.05% | 7.42% | 7.31% | 6.39% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -408.14 | -2.09 | -1.29 | -2.46 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.51 | 0.85 | 0.64 |
| Cash Conversion Cycle | 30,522.08 | 228.74 | 191.67 | 195.96 |